SecBot SecBot

BFRI

Biofrontera Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001858685 Biotech & Drug Discovery
$0.8398 +0.02 (+2.17%)
Oct 27 4:00 PM ET · prev $0.8220
Market cap
$11.7M
Nano cap
Median target
$6.00
+614% · range $3.00–9.00
Next earnings
Nov 10
in 14 days · EPS est. −$0.11
1 year
−20.8%
from $1.06 · Oct 28
30 days
−25.7%
from $1.13
52-week range
$0.5700–1.61
−48% from high · low Dec 31
Avg volume 20D
248.7K
Oct 5 spike 720.9K
Short interest
103.1K
≈0.7% of shares · −29.8%
Days to cover
1.0
at average volume
Insider net
$0
no open-market trades · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Reddit crowd
50°
Neutral · 1 mention this week
SecBot read BULLISH 2 reports · 90 days
Balance 0 bearish · 2 bullish oldest → newest, height = score
Avg score ·High conf. 2/2 ·Next Earnings date, Nov 10, 2026
Strongest BULLISH Biofrontera announced FDA approval of its supplemental New Drug Application for Ameluz (aminolevulinic acid…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.

  • InstitutionsMIXED

    Q2 2026: 2 added (0 new), 1 trimmed or exited.

  • EstimatesFLAT

    Current-quarter EPS estimate −$0.110 → −$0.110 over 90 days. 1 up, 0 down in 30 days.

  • Short sellersCOVERING

    Short interest −29.8% to 103.1K shares. 1.0 days to cover, ≈0.7% of shares.

  • TrendDOWNTREND

    29% below its 50-day average.

  • SocialQUIET

    Crowd 50° (neutral) this week from 1 mention: 0 bullish, 0 bearish. No setup call.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
GEODE CAPITAL MANAGEMENT, LLCTRIM76,689$72.5K
VANGUARD CAPITAL MANAGEMENT LLCADD71,380$67.5K
UBS Group AGDOUBLED18,518$17.5K
GEODE CAPITAL MANAGEMENT, LLCADD109,300$88.4K
CITIGROUP INCDOUBLED11,837$9.6K
UBS Group AGNEAR_EXIT1,540$1.2K
GEODE CAPITAL MANAGEMENT, LLCADD65,677$37.4K
UBS Group AGDOUBLED10,365$5.9K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

last action May 2026
12-month targets · 2 analysts

Price is below the lowest target. Median implies +614%.Targets as of Oct 27, 2026.

Recent actions
DateFirmActionRating
May 19, 2026Benchmark
DOWNGRADE
DOWNGRADESpeculative Buy
Reddit
Crowd this week 50° Neutral 0 bullish · 0 bearish
Mentions, 7 days 1 1 in posts · 0 in comments
Recent posts
r/pennystocks Neutral 6d ago
10 penny biotechs I'm watching and slowly adding for October/November 2026, and the one I got wrong in September.
1 upvotes · 1 comments
r/pennystocks Neutral 15d ago
BFRI ($0.97): FDA-approved skin cancer light therapy, $14M cap, nearly breakeven
1 upvotes · 0 comments
All social signals and their track records

Insider ledger

Form 4
$0
open-market buys or sells · 12 mo
DateInsiderTypeValue
Jul 28, 2026
Luebbert Hermann
CEO & Chairman
EXERCISE62,500 sh
Jul 28, 2026
Leffler Eugene Frederick
Chief Financial Officer
EXERCISE31,250 sh
Mar 5, 2026
Leffler Eugene Frederick
Chief Financial Officer
EXERCISE87,500 sh
Mar 5, 2026
Luebbert Hermann
CEO & Chairman
EXERCISE137,500 sh
Mar 4, 2026
Leffler Eugene Frederick
Chief Financial Officer
AWARD62,500 sh
Mar 4, 2026
Lanckriet Heikki
Director
AWARD20,000 sh
Mar 4, 2026
Jones George Patrick
Chief Commercial Officer
AWARD50,000 sh
Mar 4, 2026
Luebbert Hermann
CEO & Chairman
AWARD125,000 sh

Earnings setup

Estimates
Nov 10
reports in 14 days
−$0.11
EPS estimate, this quarter
0%
estimate change, 90 days
1↑ 0↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.11-$0.11–-$0.11+0.0%$8.3M
Next Q$0.31$0.31–$0.31+0.0%$15.8M
Current FY-$0.18-$0.18–-$0.18+0.0%$46.1M
Next FY$0.43$0.43–$0.43+0.0%$53.5M

Short side

FINRA· Oct 15, 2026
103,148
shares short
-29.8%
vs prior settlement
1.0
days to cover
≈0.7%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 28, 2026 FDA PDUFA
PDUFA: BFRI — Ameluz in superficial basal cell carcinoma (sBCC) — 2026-09-28
FDA target action date 2026-09-28 for BFRI (Biofrontera Inc.). Drug: Ameluz. Indication: superficial
Sep 14, 2026 SEC
Biofrontera announced FDA approval of its supplemental New Drug Application for Ameluz (aminolevulinic acid…
8-K — Impact 7/10
Aug 13, 2026 SEC
Biofrontera reported Q2 2026 net product revenue of $12.0M (+32.9% YoY), a net loss of $0.6M ($-0.05/share) vs a $5.3M…
8-K — Impact 7/10
Jul 28, 2026 Insider
Luebbert Hermann acquired via exercise 62,500 shares
CEO & Chairman
Jul 28, 2026 Insider
Leffler Eugene Frederick acquired via exercise 31,250 shares
Chief Financial Officer
Jun 30, 2026 Inst.
GEODE CAPITAL MANAGEMENT, LLC — TRIM
76,689 shares ($72.5K)
Jun 30, 2026 Inst.
VANGUARD CAPITAL MANAGEMENT LLC — ADD
71,380 shares ($67.5K)
May 14, 2026 SEC
Biofrontera reported Q1 2026 revenue of $10.1M (+17% YoY), gross margins expanding to ~80% from ~62%, and near-zero…
PRESS-RELEASE — Impact 7/10
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 10, 2026
Earnings date
BFRI Q3 2026 Earnings Scheduled — 2026-11-10
Recent
Oct 1, 2026
Clinical Trial
Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Moderate to Severe Acne Vulgaris With Photodynamic Therapy in Adults
Phase 2 · COMPLETED
Sep 28, 2026
FDA decision date
PDUFA: BFRI — Ameluz in superficial basal cell carcinoma (sBCC) — 2026-09-28
FDA target action date 2026-09-28 for BFRI (Biofrontera Inc.). Drug: Ameluz. Indication: superficial basal cell carcinoma (sBCC). FDA accepted sNDA…
Aug 21, 2026
Clinical Trial
Study to Evaluate the Safety, Tolerability and Efficacy of BF-200 ALA (Ameluz®) in the Field-directed Treatment of Actinic Keratosis (AK) on the Extremities and Neck/Trunk With Photodynamic Therapy (PDT) Using a RhodoLED Lamp
Phase 3 · COMPLETED
Aug 13, 2026
Earnings date
BFRI Q2 2026 Earnings Scheduled — 2026-08-13
Aug 11, 2026
Earnings date
BFRI Q2 2026 Earnings Scheduled — 2026-08-11

SecBot reports

5 filings · 1 press release · 4 bullish · 0 bearish · 1 neutral
All BFRI filing & press-release reports (6)